Relatlimab + Nivolumab

DRUG3 trials

Sponsors

Bristol-Myers Squibb, John Kirkwood

Conditions

Cancer of the StomachGastric CancerGastroesophageal JunctionLocally Advanced MelanomaMelanomaStomach Cancer

Phase 2

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

WithdrawnNCT03704077

Bristol-Myers SquibbCancer of the Stomach, Gastric Cancer, Gastroesophageal Junction +1

Start: 2019-10-31End: 2024-09-30Updated: 2020-05-19

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

CompletedNCT03743766

John KirkwoodMelanoma

Start: 2019-03-29End: 2025-07-03Updated: 2026-08-31

Unknown Phase

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

RecruitingNCT07223411

John KirkwoodLocally Advanced Melanoma

Start: 2025-11-19End: 2031-11-01Target: 20Updated: 2025-11-26

Related Papers

Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8<sup>+</sup> T cells to promote antitumor immunity.

2024-08-01100 citations

Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).

Journal of Clinical Oncology2024-06-01

818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma

Regular and Young Investigator Award Abstracts2022-11-01

Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.

Journal of Clinical Oncology2022-06-011 citations

A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.

Journal of Clinical Oncology2020-05-207 citations